Skip to main content
Log in

Pharmacokinetics of the antiviral agent 3-deazaneplanocin A

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript


The pharmacokinetics of 3-deazaneplanocin A (c3Nep), a competitive inhibitor of S-adenosyl-l-homocysteine (AdoHcy) hydrolase and novel antiviral agent, was investigated in female BALB/c mice. Animals were given a single intravenous dose of [3H]-c3Nep (0.1 mg/kg: 10 μCi), and blood and selected tissues were collected at various intervals thereafter for up to 72 h. The plasma concentration versus time data for c3Nep was best approximated by a two-compartment open model with first order elimination. The elimination half-life was 12.8 min, the area-under curve (AUC) was 3.38 μ−1. The distribution of c3Nep into tissues was not extensive. Following 30, 120 min, and 24 h after dosing, the kidneys and the liver contained the highest amount of drug, but this amount did not exceed 1 μg/g tissue. At these time periods, the majority of activity in the tissues represented labeled derivatives of c3Nep indicating that this compound was converted to stable metabolites. The presence of labeled conversion products in the blood confirmed that this drug is metabolized in vivo. The fact that c3Nep bound to plasma proteins in vitro may explain this drug’s limited tissue distribution. The half-life and tissue distribution of c3Nep were different from those of carbocyclic 3-deazaadenosine, a related adenosine nucleoside antiviral drug and AdoHcy hydrolase inhibitor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Glazer R.I., Hartman K.D., Knode M.C., et al. (1986): 3-deazaneplanocin A: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem. Biophys. Res. Commun., 135, 688–694.

    Article  PubMed  CAS  Google Scholar 

  2. Glazer R.I., Knode M.C., Tseng C.K.H., Haines D.R., Marquez V.E. (1986): 3-deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem. Pharmacol., 35, 4523–4527.

    Article  PubMed  CAS  Google Scholar 

  3. Chiang P.K., Richards H.H., Cantoni G.L. (1977): S-adenosyl-L-homocysteine hydrolase: analogues of S-adenosyl-L-homocysteine as potential inhibitors. Mol. Pharmacol., 13, 939–947.

    PubMed  CAS  Google Scholar 

  4. De Clercq E. (1987): S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol., 36, 2657–2575.

    Google Scholar 

  5. Montgomery J.A., Clayton S.J., Thomas H.J., et al. (1982): Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target. J. Med. Chem., 25, 626–629.

    Article  PubMed  CAS  Google Scholar 

  6. Cools M., De Clercq E. (1989): Correlation between the antiviral activity of acyclic and carbocyclic adenosine analogues in murine L929 cells and their inhibitory effect on L929 cell S-adenosylhomocysteine hydrolase. Biochem. Pharmacol., 38, 1061–1067.

    Article  PubMed  CAS  Google Scholar 

  7. De Clercq E., Cools M., Balzarini J., et al. (1989): Broad-spectrum antiviral activities of neplanocin A and 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob. Agents Chemother., 33, 1291–1297.

    PubMed  Google Scholar 

  8. Oxenrider K.A., Bu G., Sitz T.O. (1993): Adenosine analogs inhibit the guanine-7-methylation of mRNA cap structures. FEBS Lett., 316, 273–277.

    Article  PubMed  CAS  Google Scholar 

  9. Chiang P.K., Burbelo P.D., Brugh S.A., Gordon R.K., Fukuda K., Yamada Y. (1992): Activation of collagen IV gene expression of F9 teratocarcinoma cells by 3-deazaadenosine analogs. J. Biol. Chem., 267, 4988–4991.

    PubMed  CAS  Google Scholar 

  10. Tseng C.K.H., Marquez V.E., Fuller F.W., et al. (1989): Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem., 32, 1442–1446.

    Article  PubMed  CAS  Google Scholar 

  11. Coulombe Jr R.A., Huie J.M., Sharma R.P., Huggins J.W. (1993): Pharmacokinetics of the antiviral agent carbocyclic 3-deazadenosine. Drug Metab. Dispos., 21, 555–559.

    PubMed  CAS  Google Scholar 

  12. El Dareer S.M., Tillery K.F., Rose L.M., Struck R.F., Hill D.L. (1990): Disposition and metabolism of carbovir in mice dosed intravenously or orally. Drug Metab. Dispos., 18, 842–845.

    PubMed  CAS  Google Scholar 

  13. Ibrahim S.S., Boudinot F.D. (1991): Pharmacokinetics of 2′,3′-dideoxycytidine after high dose administration to rats. J. Pharm. Sci., 80, 36–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Coulombe, R.A., Sharma, R.P. & Huggins, J.W. Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. European Journal of Drug Metabolism and Pharmacokinetics 20, 197–202 (1995).

Download citation

  • Received:

  • Issue Date:

  • DOI: